SwePub
Sök i LIBRIS databas

  Utökad sökning

(WFRF:(Baum Richard P.))
 

Sökning: (WFRF:(Baum Richard P.)) > Molecular profiling...

LIBRIS Formathandbok  (Information om MARC21)
FältnamnIndikatorerMetadata
00003723naa a2200385 4500
001oai:DiVA.org:uu-523466
003SwePub
008240221s2020 | |||||||||||000 ||eng|
0247 a https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-5234662 URI
0247 a https://doi.org/10.1016/S1470-2045(20)30323-52 DOI
040 a (SwePub)uu
041 a engb eng
042 9 SwePub
072 7a ref2 swepub-contenttype
072 7a for2 swepub-publicationtype
1001 a Bodei, Lisau Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA.4 aut
2451 0a Molecular profiling of neuroendocrine tumours to predict response and toxicity to peptide receptor radionuclide therapy
264 1b Elsevier,c 2020
338 a print2 rdacarrier
520 a Peptide receptor radionuclide therapy (PRRT) is a type of radiotherapy that targets peptide receptors and is typically used for neuroendocrine tumours (NETs). Some of the key challenges in its use are the prediction of efficacy and toxicity, patient selection, and response optimisation. In this Review, we assess current knowledge on the molecular profile of NETs and the strategies and tools used to predict, monitor, and assess the toxicity of PRRT. The few mutations in tumour genes that can be evaluated (eg, ATM and DAXX) are limited to pancreatic NETs and are most likely not informative. Assays that are transcriptomic or based on genes are effective in the prediction of radiotherapy response in other cancers. A blood-based assay for eight genes (the PRRT prediction quotient [PPQ]) has an overall accuracy of 95% for predicting responses to PRRT in NETs. No molecular markers exist that can predict the toxicity of PRRT. Candidate molecular targets include seven single nucleotide polymorphisms (SNPs) that are susceptible to radiation. Transcriptomic evaluations of blood and a combination of gene expression and specific SNPs, assessed by machine learning with algorithms that are tumour-specific, might yield molecular tools to enhance the efficacy and safety of PRRT.
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Cancer och onkologi0 (SwePub)302032 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Cancer and Oncology0 (SwePub)302032 hsv//eng
650 7a MEDICIN OCH HÄLSOVETENSKAPx Klinisk medicinx Endokrinologi och diabetes0 (SwePub)302052 hsv//swe
650 7a MEDICAL AND HEALTH SCIENCESx Clinical Medicinex Endocrinology and Diabetes0 (SwePub)302052 hsv//eng
7001 a Schoeder, Heikou Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA.4 aut
7001 a Baum, Richard P.u Ctr Adv Radiomol Precis Oncol, CURANOSTICUM, Wiesbaden, Germany.4 aut
7001 a Herrmann, Kenu Univ Duisburg Essen, Essen Univ Hosp, Dept Nucl Med, Essen, Germany.4 aut
7001 a Strosberg, Jonathanu H Lee Moffitt Canc Ctr & Res Inst, Dept Gastrointestinal Oncol, Tampa, FL USA.4 aut
7001 a Caplin, Martynu Royal Free Hosp, Dept Gastroenterol, Neuroendocrine Tumour Unit, London, England.4 aut
7001 a Öberg, Kjell,d 1946-u Uppsala universitet,Endokrin tumörbiologi4 aut0 (Swepub:uu)kjellob
7001 a Modlin, Irvin M.u Yale Univ, Yale Univ Sch Med, Dept Surg, New Haven, CT USA.4 aut
7102 a Mem Sloan Kettering Canc Ctr, Dept Radiol, Mol Imaging & Therapy Serv, New York, NY 10065 USA.b Ctr Adv Radiomol Precis Oncol, CURANOSTICUM, Wiesbaden, Germany.4 org
7730 t The Lancet Oncologyd : Elsevierg 21:9, s. E431-E443q 21:9<E431-E443x 1470-2045x 1474-5488
8564 8u https://urn.kb.se/resolve?urn=urn:nbn:se:uu:diva-523466
8564 8u https://doi.org/10.1016/S1470-2045(20)30323-5

Hitta via bibliotek

Till lärosätets databas

Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy